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a b s t r a c t
C5a receptor (C5aR) is one of the major chemoattractant receptors of the druggable proteome that binds
C5a, the proinﬂammatory polypeptide of complement cascade, triggering inﬂammation and SEPSIS.
Here, we report the model structures of C5aR in both inactive and peptide agonist (YSFKPMPLaR; a¼D-
Ala) bound meta-active state. Assembled in CYANA and evolved over molecular dynamics (MD) in POPC
bilayer, the inactive C5aR demonstrates a topologically unique compact heptahelical bundle topology
harboring a β-hairpin in extracellular loop 2 (ECL2), derived from the atomistic folding simulations. The
peptide agonist bound meta-active C5aR deciphers the “site2” at an atomistic resolution in the
extracellular surface (ECS), in contrast to the previously hypothesized inter-helical crevice. With
estimated KiE2.75 μM, the meta-active C5aR excellently rationalizes the IC50 (0.1–13 μM) and EC50
(0.01–6 μM) values, displayed by the peptide agonist in several signaling studies. Moreover, with
KiE5.3105 μM, the “site2” also illustrates selectivity, by discriminating the stereochemical mutant
peptide (YSFkPMPLaR; k¼D-Lys), known to be inert toward C5aR, up to 1 mM concentration.
Topologically juxtaposed between the structures of rhodopsin and CXCR1, the C5aR models also display
excellent structural correlations with the other G-protein coupled receptors (GPCRs). The models
elaborated in the current study unravel many important structural insights previously not known for
regulating the agonist binding and activation mechanism of C5aR.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
C5aR is one of the two chemoattractant receptors [1] phylo-
genetically related to the rhodopsin subfamily of GPCRs found in
human genome. C5aR interacts with C5a, the most potent proteo-
lytic by-product of complement component 5 (C5) that triggers
numerous proinﬂammatory and immunosuppressive disorders,
including SEPSIS [2]. Thus, pharmaceutical industries have identi-
ﬁed the C5aR as a potential target for development of future anti-
inﬂammatory therapies [3].
Advances in protein engineering, including the membrane
reconstitution techniques, have been phenomenal for structural
studies of GPCRs [4–23]. However, the growing list still lacks many
rhodopsin family GPCRs including the C5aR, whose native struc-
tures both in inactive and agonist bound meta-active states are yet
to be determined. Nevertheless, biochemical studies suggest that
C5aR harbors two distinct binding sites for C5a, “site1” in N-
terminus and “site2” in inter-helical crevice [24], obscured by the
ECL2 in the inactive state [25]. For high afﬁnity binding and
signaling, the “site1” on C5aR engages the bulk of C5a, whereas
“site2” engages the C-terminus of C5a. In agreement, it is evi-
denced that stereochemically engineered linear peptide agonist
[26] (YSFKPMPLaR), carved out of the C-terminus of C5a [27]
(ISHKDMQLGR, identical residues), potentially activates the C5aR
signaling axis solo, albeit with weak potency. In addition, it is also
noted that the proteolytic removal of the last C-terminal residue
on C5a (des-R74-C5a) severely down regulates the C5aR signaling
[28–34], which suggests that perhaps the interaction of the
agonist at the “site2” plays a signiﬁcant role over “site1” for
triggering downstream signaling in C5aR. However, the precise
intermolecular interactions between the C-terminus of C5a or the
peptide agonist with C5aR, still remains a mystery, due to the
unavailability of any such structural complexes, at an atomistic
resolution. In the absence of structural data, several hypotheses
have been postulated for C5a–C5aR interactions, purely based on
the mutational studies performed on both C5a and C5aR. Inter-
estingly, most of the functional data reported for C5a–C5aR or
peptide agonist–C5aR has not been independently quantiﬁed with
a full-ﬂedged molecular model of C5aR. Even the coarse grain
molecular model [35] proposed earlier for C5a–C5aR appears
inadequate for precisely probing the interactions, respectively at
the “site1” and “site2” of C5aR. As a result, the exact molecular
mechanism underlying the agonist binding and selectivity in C5aR
is still unclear, which greatly hinders the advancement of the
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prospective discovery and development of C5aR targeted
therapeutics.
On the other hand, it is also not clear how C5aR switches from
inactive to meta-active conformer that facilitates the agonist
binding, followed by the interaction with G-proteins leading to
the fully active state. The popular theory describes that activation
of GPCRs involves a series of “molecular switches” [36] conserved
across the “microdomains” [37] of the receptors. In particular, the
GPCR activation involves the rotamer toggling on TM6 [38,39] or
the loss of the conserved ionic lock interaction between TM3 and
TM6 [40,41], facilitating the movement of TM3–TM6 at the
intracellular face of the receptors, resulting in the subsequent
binding and activation of G-proteins. Interestingly, C5aR does not
feature the ionic lock, due to the lack of appropriate residues on
TM3 and TM6 [42]. In fact the popular notion does not ﬁt always,
as nearly 80% of the rhodopsin family receptors do not have the
right residues to support either the “rotamer toggling” or the
“ionic lock” or sometimes the both [43]. So it is natural to wonder,
whether this conformational transition from inactive to agonist
ready meta-active conformer in C5aR requires the agonist binding
(IF: induced ﬁt) ﬁrst or the agonist ready meta-active conformers
are readily available due to the population dynamics of C5aR
conformational microstates (CS: conformational selection) in tis-
sue bilayers [44]. Surprisingly, no such information is currently
available in the literature to clearly understand the activation
mechanism of C5aR.
In the absence of a structure of C5aR, the present study aims to
(1) generate a highly reﬁned unique model structure of inactive
C5aR, by recruiting the available structural data on GPCRs, (2) sys-
tematically decipher the meta-active conformer of C5aR with
“site2”, (3) identify the residues in “site2” involved in peptide
agonist binding and selectivity, in agreement with the reported
binding and signaling studies [25,28–34,42,45–50], (4) test the
stability of the C5aR–peptide agonist complex in POPC bilayer for
further rationalizing the interaction speciﬁcity in light of C5a, and
(5) understand the activation mechanism of C5aR triggered by the
conformational transition from the inactive to meta-active state in
light of other GPCRs.
2. Material and methods
2.1. Data sets and general computational methods
PDB coordinates of 20 rhodopsin family GPCRs (14 inactive and
6 active) [4–23] were downloaded from www.rcsb.org. Primary
sequence of C5aR was obtained from www.gpcr.org/7tm/. Visua-
lization, analysis and presentation of model structure were per-
formed respectively in PyMOL (The PyMOL Molecular Graphics
System, Version 1.1r1, Schrödinger, LLC), MoLMoL [51], and Dis-
covery studio (Accelrys). MoLMoL was implemented speciﬁcally
for calculating the interhelical angles between the helix axes.
Sequence alignments of receptors and of individual helices were
achieved using ClustalX [52], which was further curated manually.
Data were plotted in GraphPad Prism (version 6 for Windows,
GraphPad Software, La Jolla California USA, www.graphpad.com).
Solvent accessible surface area (SASA) of the receptors and of
ligand binding sites were calculated with Naccess [53] with default
van der Waals radii, by rolling a probe of radius 1.4 Å around the
van der Waals surface. “Cation-π” angles were calculated as
described [54] using the in house program. TM residues were
numbered following Ballesteros–Weinstein system [37]. The two
templates implemented for modeling each TMs of C5aR were
selected from the matrix of 714 helices of inactive receptors,
based on the highest sequence identity and similarity with TMs in
C5aR. Homology models of the individual TMs in C5aR were
achieved by recruiting two distinct templates in MODELLER [55],
which were subsequently energy minimized and subjected to
further analysis.
2.2. MD simulation in explicit water
The ECL2s of CXCR4 and β2AR were directly extracted from the
crystal structures. The resulting peptides were end capped (COCH3
at N-terminus and CONH2 at C-terminus) and then subjected to
careful energy minimization in a cubic box with periodic bound-
ary, appropriately surrounded with simple point charge (SPC)
water model, by recruiting the gromos-96 43a1 force ﬁeld in
GROMACS package [56]. Numerical integrations were performed
in step size of 2 fs and coordinates were updated every 5 ps.
Solvent density was set to the value corresponding to 1 atm at
300 K. Peptide and solvent were coupled independently to a
modiﬁed Berendsen bath at 300 K, to the coupling time constant
0.1 ps. The appropriately equilibrated ECL2 structures were further
subjected to MD studies at 300 K for 50 ns. The folding simulations
for the ECL2 polypeptide of C5aR were initiated by implementing
the above protocol, respectively validated against the ECL2s of
CXCR4 and β2AR receptors. The end capped extended ECL2
polypeptide [Ac-Y174-RVVREEYFPPKVLCGVDYSHDKR-R198-NH2;
ϕ, ψ¼71201, ϕ, ψ¼601, 1201 for proline] of C5aR was modeled
using the in-house program PDBmake. Initially, the polypeptide
was subjected to MD for 2 ns at 300 K. The resultant, partially
collapsed random conformation of ECL2 was further subjected to
folding studies, respectively, at 300 K and 310 K over 100 ns in
explicit water. The 310 K trajectory was repeated again following
the identical protocol. Analyses of the trajectories were achieved
by recruiting the modules built into GROMACS.
2.3. CYANA model and MD simulation in POPC bilayer
The initial model of C5aR was assembled in CYANA [57].
Distance restraints used as inputs for structural modeling of
C5aR in CYANA were directly calculated from the individual
secondary structures of TMs and ECL2. Utility tools in Gromacs
provided the dihedral angles (ϕ, ψ) of the individual amino acids in
TMs and in folded ECL2. This alternatively helped in setting up the
appropriate range of angular constraints for individual amino
acids, which was subsequently used as input in CYANA. Hydrogen
bond constraints were derived from the individual TMs and ECL2.
The above restraints, including the interhelical distance restraints
derived from the CXCR1 based template helped the structural
modeling of C5aR, by appropriately guiding the conformation of
other I / ECLs in CYANA. The models were screened for violations
in amide geometry and backbone dihedral angles at individual
amino acids. The best CYANA model with minimal violations was
subjected to further reﬁnements in MD studies over 250 ns, at
300 K in POPC [1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocho-
line] bilayer. We preferred to use POPC bilayer in our studies, as
it has been mostly used as a model lipid for GPCR simulations
[18,20,58,59]. Following the InﬂateGRO approach [60], the CYANA
modeled C5aR was inserted into the pre-equilibrated POPC bilayer
(Prof. Peter Tieleman, Univ. Calgary) having 64 POPC molecules,
each in upper and lower leaﬂets. POPC was packed around the
C5aR until the areas per lipid (A) values were little over its
reported experimental value (A¼68.371.5 Å2) [61,62]. The ﬁnal
system with 123 POPC molecules was neutralized by randomly
placing 13 chloride ions that contained a total of 4620 water
molecules. The system was equilibrated twice, ﬁrst for 500 ps
under NVT, followed by 1 ns under NPT conditions prior to the MD
studies. Given the phase transition of pure POPC at 270 K [62,63],
the MD studies were done at 300 K (modiﬁed Berendsen) with
C5aR, POPC in one group and water and ions in another group.
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Numerical integrations were performed in step size of 2 fs and
coordinates were updated every 5 ps. Bonds were constrained
with LINCS with order 4. Non-bonded pair list cut-off was 1.2 nm
with a grid function. PME was implemented for electrostatic
calculations. The peptide agonist bound meta-active conformer
of C5aR was also subjected to MD studies over 250 ns in POPC
bilayer (system contained 123 POPC, 4373 water molecules, and 15
chloride ions) as described above. The stereochemical mutant
peptide that displayed a weak binding afﬁnity toward the meta-
active conformer of C5aR was not subjected to MD studies in POPC
bilayer. In order to maintain the homogeneity throughout our
studies, we also used the gromos-96 43a1 force ﬁeld for lipid
bilayer simulation. We did not try any other force ﬁelds in
GROMACS. The MD trajectories were analyzed using the modules
built into GROMACS.
2.4. Conformational clustering
Conformational clustering was performed (every 5 ps) as
described [64], to the RMSD cut-offr3 Å for the folding trajec-
tories of ECL2 in water, as both ECL2s in CXCR4 and β2AR displayed
a backbone RMSD over 3 Å. However, cut-off was reduced
tor1.5 Å, while analyzing the trajectories of folded ECL2s in
water. Clusters havingZ100 conformers were considered as major
microstates/clusters. On the other hand, conformational clustering
of the C5aR in POPC bilayer was performed (every 10 ps) to the
RMSD cut-offr1.5 Å and the free energies of the microstates were
derived from the relative populations of individual microstates,
using the following equation [64]:
ΔGA-B ¼ κBT lnðPAPBÞ ð1Þ
where κB is the Boltzmann constant, PA and PB are the relative
probabilities of ﬁnding the system in states A and B respectively, at
temperature T. PA and PB are taken as the number of structures in
microstates A and B respectively. For C5aR, clusters with minimum
200 conformers were selected as major microstates. The clusters
were ranked based on their free energies. Cluster with highest
number of conformers represented the inactive state of C5aR.
2.5. Docking of the peptide agonist
The linear YSFKPMPLaR agonist was modeled with PDBmake
using the 2D NMR data as described [26], which was further
subjected to energy minimization prior to the docking studies. The
stereochemical mutant YSFkPMPLaR of the peptide agonist was
also modeled similarly and energy minimized. The ﬂexible ligand
docking (RMSD tolerance of 5 Å), followed by a rigid docking
(RMSD tolerance of 2 Å), was performed with AutoDock4.2 [65] for
a population size of 150, implementing the genetic search algo-
rithm with maximum number of generation set to 27,000. Struc-
turally distinct conformational clusters of the peptides were
ranked in terms of increasing energy. The best interacting con-
formers, respectively of the peptide agonist and the C5aR, repre-
sented the agonist peptide bound meta-active state of C5aR.
Similar protocols were also used for docking the stereochemical
mutant peptide to the meta-active conformer of C5aR.
3. Results and discussion
3.1. Structural analysis of the GPCRs for modeling C5aR
In our quest for a model structure of C5aR, we analyzed 14
inactive and 6 active structures of GPCRs (Table S1) [4–23]. The
structural analysis revealed that GPCRs share a canonical hepta
helical bundle topology with a short 8th helix at the intra cellular
side of the C-terminus. In addition, it is also evidenced that barring
ECL2 (Fig. S1), the longest polypeptide loop, no other intra- and
extra-cellular loops (I/ECLs) in GPCRs demonstrate structural
diversity. It is interesting to note that except the rhodopsin [4], a
major part of the N- and C-terminus is structurally unresolved in
most of the GPCRs, including several protein ligand binding
chemokine receptors, such as CXCR1, CXCR4 and CCR5. Rhodopsin
is an exception, as it harbors a covalently linked non-protein
ligand within its helical bundle, which activates the receptor by
absorbing light. However, similar to the chemokine receptors, the
N-terminus of C5aR (T7-K28) is also unordered, as evidenced in
complex with the immune evasion protein CHIPS [66], established
by NMR structural studies. The structural analysis described here,
including the previous mutational studies [42], prompted us to
model a truncated structure of C5aR (D27-P316; lacks 26 residues
on N-terminus and 34 residues on C-terminus), harboring a
possible folded structure of ECL2. Despite the canonical nature of
transmembrane regions, GPCRs are topologically distinguishable,
which makes them structurally unique. In order to invoke that
certain uniqueness into the C5aR, direct template based homology
models were avoided in our study.
3.2. Prediction and homology models of the TMs in C5aR
Among the inactive GPCRs (Table S2), the chemokine receptors
CXCR1 (27.4/52) [14] and CXCR4 (24.5/50) [7], including the μ-
opioid (27/53.4) [13] receptor, displayed a relatively high %
sequence identity/similarity with C5aR. Out of the two closest
phylogenetic siblings, the ligand free inactive structure of CXCR1
was preferred over CXCR4 for predicting the length of TMs in
C5aR. Further, the homology models (Fig. S2) of the predicted TMs
(TM1: P36-F65, TM2: N71-H99, TM3: A107-V138, TM4: A150-L173,
TM5: E199-R228, TM6: R236-V260, TM7: C272-A303, and TM8:
Q305-L315) were respectively built in MODELLER [55], by recruit-
ing the two distinct templates, screened out for each TMs, from
the matrix of 714 helices (Table S3) of inactive GPCRs. Integrity
of the models were tested thoroughly prior to the further studies.
3.3. Modeling the folded structure of the ECL2 in C5aR
In silico folding of extended polypeptides [67–71], recruiting
the molecular dynamics (MD) techniques have been very success-
ful in past for predicting the putative structures of small peptides
and proteins. Thus, to predict the possible folded structure of ECL2
in C5aR, the extended ECL2 polypeptide was subjected to an all
atom folding simulation in explicit water, by recruiting the
GROMACS [56], as described in Section 2.2. First, the MD protocols
were benchmarked, respectively against the ECL2s of CXCR4 and
β2-adrenergic receptors [5,7] over 50 ns at 300 K. Both the ECL2s
lacked the restraint of the conserved disulﬁde bond, including the
transmembrane helices over the period of MD. It is noteworthy
that the disruption of the structurally conserved disulﬁde linkage
between the ECL2 and the TM3/ECL1 is known to affect the overall
expression, maturation and folding of GPCRs. However, it is not
established either biophysically or structurally that lack of this
conserved disulﬁde bond particularly affects the folding and the
structural integrity of the ECL2 in GPCRs. The results summarized
in Fig. S3 and S4 indicate that the absence of transmembrane
helices, including the ECL2-TM3 conserved disulﬁde bond does not
perturb the structural integrity of the ECL2s signiﬁcantly, which
further suggests that the ECL2s are also among the independently
foldable structural motifs in GPCRs. However, in the absence of
both the conserved disulﬁde bond and the connecting helices, the
ECL2s display high conformational ﬂexibility (backbone
RMSDE4 Å and 5.87 Å, respectively for CXCR4 and β2AR, Fig.
S5), which is not surprising, as GPCRs are inherently dynamic and
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are known for their modularity in ligand recognition and func-
tional diversity [72].
The benchmarked protocol was then implemented for evaluat-
ing the folded structure of the ECL2 in C5aR. The folding simula-
tions were started, respectively, at 300 K and 310 K, from the
partially collapsed random conformation (Fig. S6) obtained from
the initial 2 ns MD study at 300 K. Compared to 310 K, the 300 K
trajectory did not progress appreciably in folding pathways over
50 ns, as it got stuck in some sort of local minima, similar to
a molten globule state (Fig. S7). Thus, the 300 K trajectory was
not extended further. However, the 310 K trajectory displayed
signatures of folding as early as 6 ns, which transformed into
a well folded β-hairpin at around 9 ns (Fig. 1) and remained
stable over 100 ns. A repeat run at 310 K also produced similar
results (Fig. S8).
Cluster analysis (Fig. S9) suggested that the β-hairpin structure
could be the major conformational microstate accessible to the
ECL2 of C5aR. To probe it further, the central structure of the
largest cluster was subjected to MD studies at 300 K over 50 ns.
The results summarized in Fig. 2 suggest that indeed the ECL2 in
C5aR harbors a topologically and structurally stable β-hairpin that
spans from P184-H194 with C188-G189-V190 in loop conforma-
tions. Sequence analysis of the β-hairpin structures of the ECL2s
(Table S4) across the GPCRs revealed that the ECL2 in C5aR shares
the highest sequence identity/similarity (28%/48%) with the ECL2
of rhodopsin [4]. However, the folded ECL2 of C5aR demonstrates a
distinctly different structure from the ECL2 of rhodopsin (back-
bone RMSD 6.8 Å, Fig. S10b). Further structural comparison indi-
cated that while the conserved C188 adopted loop conformations
in ECL2 of C5aR, the conserved C187 in rhodopsin adopted the β-
sheet conformation (Fig. S10a). In contrast, the rhodopsin template
based homology model of C5aR-ECL2 (Fig. S10c) displays a β-
hairpin with C188 in the β-sheet region, as observed in rhodopsin
(backbone RMSD 3 Å; 3CAP, www.gpcr.org/7tm/), spanning from
E179-V190 with P183-P184-K185 in loop conformations. It is
noteworthy that the ECL2 structure in C5aR obtained out of the
folding simulation studies does not involve any such structural
bias. Moreover, the β-hairpin loop in the folded ECL2 of C5aR
features a glycine (C188-G189-V190), which is in agreement with
Z50% ECL2s in GPCRS with a β-hairpin structure. It is also
interesting that similar to the folded ECL2 of C5aR, the ECL2 of
rhodopsin also carries an additional unpaired cysteine (C185) in its
hairpin loop (G182-M183-Q184), beside the conserved C187 on the
β-sheet (Fig. S10b) linked to C1103.25 in TM3. This further assures
that the folded structure obtained in the absence of the conserved
disulﬁde bond for the ECL2 of C5aR is indeed of high quality.
3.4. Structural assembly of C5aR in CYANA
CYANA [57] is an excellent tool that converts nuclear overhauser
effect (NOE) intensities to distance restraints and further uses it as
inputs for modeling the NMR structures of peptides and proteins.
The hydrogen bond and the dihedral constraints used in CYANA are
usually derived from the chemical shift index data, which provides
information about the secondary structure of the proteins or
peptides. In our studies, the very same principle of CYANA was
harnessed for assembling the distance restraints based model
structures of C5aR. In the absence of NOE data, the distance and
other restraints used as inputs in CYANA were directly calculated
from the independently modeled secondary structures of the TMs
and ECL2, by recruiting the utility tools available in GROMACS or in
other visualization softwares. Given the paucity of secondary
structures in other I/ECLs, CYANA was allowed to model them
appropriately, in the presence of 3981 distance restraints (includes
interhelical restraints), 562 dihedral constraints, and 360 hydrogen
bond constraints, derived from the individual TMs and ECL2. As
noted in Table S3, 5 out of the 7 TMs in C5aR share over 50%
sequence similarity with CXCR1 helices. Thus, the interhelical
distance restraints used in CYANA, for modeling C5aR were derived
from the CXCR1 template. The C188 being conserved in 90% of
GPCRs [25] was assumed to form a disulﬁde bond with C1093.25
(TM3) in C5aR. Prior experimental studies have identiﬁed D27/S30
on N-terminus and S272 on third extracellular loop (ECL3) as
important residues [42] on C5aR that upon mutation to cysteines,
perhaps introduce a N-terminus-ECL3 disulﬁde bond, as observed
in chemokine receptors CXCR4, CXCR1 and CCR5 [7,14,21]. Thus,
structural modeling of C5aR in CYANA also involved an additional
restraint between S30 and S272, which was removed subsequently
during energy minimization steps.
3.5. Reﬁnement of C5aR model structure
The resultant best model withr5% violation was subjected to
further reﬁnements over 250 ns of MD simulations in POPC bilayer
(Fig. S11), following the InﬂateGRO method, as described in
Section 2.3. The presence of POPC bilayer helped the CYANA model
to attain an equilibrated conformation over time. Given the slow
conformational transition in bilayer, cluster analysis of the system
provided only 7 major conformational microstates of C5aR (Fig.
S12). With a backbone RMSD4.68 Å from the CYANA model, the
central structure of the microstate 1 (16,061 conformers) with
lowest energy was chosen to represent the inactive state of C5aR
(Fig. 3). The inactive C5aR with TM1: P36-F64, TM2: F75-Q98,
TM3: I111-F139, TM4: W154-F172, TM5: E199-R228, TM6: L241-
V260, TM7: F275-V302 and TM8: F307-L315 displayed minor
deviation from the previously predicted TM lengths (Fig. S2).
Overall, the inactive C5aR, presented in Fig. 3, displays a compact
hepta helical bundle topology with a truncated N- and C-terminus,
including three I/ECLs with a perfectly folded β-hairpin in ECL2
(L173-R198). The C188 on ECL2 form a disulﬁde bond with the
Fig. 1. Folding trajectory of the extended ECL2 polypeptide in C5aR demonstrating
the progress of folding over 100 ns at 310 K in explicit water.
Fig. 2. Monitoring the structural stability of the β-hairpin obtained for the ECL2 of
C5aR, over 50 ns of MD in explicit water at 300 K (left). Structural superposition of
the folded β-hairpin at 0 ns (red) with the central conformer of the major
microstate (blue) evolved over 50 ns, displaying backbone RMSD of 1.3 Å (right).
S. Rana, A.R. Sahoo / Biochemistry and Biophysics Reports 1 (2015) 85–9688
C109 on TM3/ECL1, which covers the interhelical crevice in C5aR,
as observed respectively in rhodopsin and CXCR1 receptors.
3.6. Structural comparison of C5aR with other GPCRs
The model structure of C5aR, presented in Fig. 3, is unique in
nature, as no such reﬁned model structure has been postulated for
C5aR in the literature so far. To probe its topological uniqueness,
the model C5aR was further validated against the inactive struc-
tures of other GPCRs. As noted in Table S5, the model displays
excellent structural correlation with the other reported inactive
GPCRs. As evidenced, most of the ICL3 engineered, ligand bound
inactive GPCRs, shares E0.6–5 Å backbone RMSD with each other,
whereas rhodopsin displaysE1.8–5.8 Å backbone RMSD across
the inactive GPCRs (Table S5). In contrast, the C5aR (Fig. 3)
displaysE4.6–6.5 Å backbone RMSD with other inactive GPCRs,
including the CXCR1 (5.3 Å), which also sharesE5.8–7.9 Å back-
bone RMSD with other inactive GPCRs (Table S5). It is noteworthy
that the structure of the inactive C5aR (Fig. 3) is perfectly
juxtaposed between the structures of rhodopsin and CXCR1. It is
interesting that the phylogenetically related receptors such as
CXCR1 and CXCR4 also share a backbone RMSD over 6.5 Å, which
makes them topologically distinct. On the other hand, a CXCR4
template (3rd best in homology, Table S2) based homology model
of C5aR (3OE6, www.gpcr.org/7tm/) display only a backbone
RMSD of 0.5 Å from CXCR4, making them topologically indistin-
guishable from each other. Interestingly, with backbone
RMSDE6 Å from CXCR4, the C5aR model structure presented in
this study is both structurally and topologically unique.
3.7. Interhelical angle analysis of GPCRs compared with C5aR
With a common hepta helical bundle topology, GPCRs are
incredibly smart in decoding messages carried out by a variety of
ligands. It is certain that receptors undergo some kind of con-
formational arrangement to correctly decode the variety of signals.
Given the fact that these receptors are packed inside the tissue
bilayer, the degree of conformational freedom should be rather
minimum. In such a scenario, the interhelical angle could be one of
the important topological descriptors that can help in under-
standing the gradual conformational change within the helix
bundle, associated with the transition from inactive to meta-
active to fully active conformations.
To further study the model structure of inactive C5aR, the
interhelical angles (Θ, Fig. S13) between the helix axes were
analyzed in 14 inactive and 6 active GPCRs. (Table S6). The result
summarized in Table S6 suggests that the common canonical
topology also share a common mean Θ value across the GPCRs
(SD of 73–81 for inactive and SD of72–81 for meta-active
GPCRs), irrespective of the % sequence homology, location of
binding sites and the type of the bound ligands. On comparison,
the inactive C5aRs also displayed similar Θ values (Table S7),
matching signiﬁcantly with the chemokine receptors CXCR1,
CXCR4, and CCR5 (Table S8) [7,14,21]. The observed similarity
with the reported structures further suggests that the topological
uniqueness in C5aR is not a result of unusual interhelical packing
and indeed the models are of high quality.
3.8. Conformational scanning for a probable “site2” on C5aR
Evaluation of the ligand free inactive state of CXCR1 and
antagonist bound inactive state of CXCR4 provides a contrasting
snapshot of ECS and its modularity to present an active site on
exposure to ligands (Fig. S14). While the inactive CXCR1 lacks an
active site, the CXCR4 demonstrate an active site on the ECS. Due
to the limited structural information, it cannot be clearly estab-
lished, whether the availability of an active site in the ECS of
CXCR4 is primarily due to CS or IF mechanism [44] is recruited
post exposure to the ligand. However, the modularity in ECS could
be unique to native peptide/protein binding receptors, as the
ligand is generally big in size, compared to the many small
molecule (non-protein) binding rhodopsin family GPCRs [5,9–
11,13,15,19,21], where ligand binding sites are usually located
little deeper into the interhelical crevices.
We desired to investigate whether such modularity to accom-
modate a polypeptide ligand exists in the ECS of C5aR. For a
possible answer, the 7 major microstates of C5aR obtained over
250 ns of MD simulation in POPC bilayer were further energeti-
cally ranked as described (Fig. S15a). Among the 3 top high energy
microstates of C5aR, microstate 6 with 178 conformers displayed
highest number of conformational transition (Fig. S15b) and thus,
subjected to further structural and surface area analysis. Surpris-
ingly, several conformers in microstate 6 displayed features of an
apparent active “site2” on ECS, in contrast to the interhelical
crevice, which was visibly absent on the conformers of microstate
1, representing the inactive state of C5aR (Figs. 3 and S14). With no
trace of a ligand, the availability of an apparent active “site2” on
ECS of C5aR is surely a result of conformational transition within
the bilayer.
3.9. Deciphering the afﬁnity of the YSFKPMPLaR agonist toward the
“site2” on C5aR
To decipher the best meta-active conformer of C5aR from the
pool of conformers in microstate 6, we recruited AutoDock [65] to
scan the apparent afﬁnity of the “site2” toward the linear dec-
apeptide agonist YSFKPMPLaR (Fig. S16a) [26]. The peptide agonist
is known to target the “site2” of C5aR with relatively high afﬁnity
(Table S9) and thus was chosen as the preferred molecular probe
over the wild type C-terminus peptide of C5a. It is also evidenced
that the peptide agonist triggers C5aR signaling in several mam-
malian tissues (EC50E0.01–6 μM), including the engineered yeast
[42], albeit with weak potency (IC50E0.1–13 μM) compared to
C5a [73–77].
Fig. 3. The unique heptahelical bundle topology of the inactive C5aR with
truncated N- and C-terminus, featuring three I/ECLs, including the β-hairpin in
ECL2 derived from the atomistic folding simulation studies. Topological features are
labeled and highlighted. The conserved disulﬁde linkage is highlighted in yellow.
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Surprisingly, in agreement with the experiments (Table S9), one
of the conformer from the microstate 6 displayed a strong binding
afﬁnity (KiE2.75 μM, 7.59 kcal/mole) for the peptide agonist, and
thus was qualiﬁed as the meta-active conformer of C5aR (Fig. 4a). In
addition, the meta-active conformer of C5aR also displayed selectiv-
ity by discriminating (KiE5.3105 μM, 0.38 kcal/mole) the
stereochemical mutant of the peptide agonist YSFkPMPLaR [78] that
replaces the L-Lys on the peptide agonist with a D-Lys (Fig. S16b). The
result is also in agreement with the previous functional data [78],
where it is demonstrated that the mutant peptide is inert toward
C5aR up to 1 mM concentration. This further justiﬁes the worthiness
of the “site2” on the meta-active conformer of C5aR (Fig. 4b).
3.10. Mechanism of the YSFKPMPLaR agonist binding and selectivity
at the “site2” of C5aR
The YSFKPMPLaR agonist displays a signiﬁcant conformational
change with a backbone RMSD of E2.9 Å, post binding to the ECS
of C5aR (Fig. S17a). The speciﬁc interactions driving the conforma-
tional change are detailed in Fig. 5a (Table S10, Fig. S17b). While
Y1-R34, S2-T32 and R10-D191, including the termini (NH3þ-E269
and COO-K185) help in anchoring the peptide agonist to C5aR,
the K4 of the agonist occupies the crucial pocket on the ECS
(Figs. 4b, 5a and S17b) of the C5aR. This favors a strong “cation-π”
[79] as well as the hydrogen bond interaction between the K4 of
the agonist and the F2757.28 (beginning of TM7) of C5aR, triggering
the binding afﬁnity and perhaps the signaling in C5aR [46].
On the other hand, the stereochemical mutation [78] (L-Lys/D-
Lys) not only alters the conformation of K4 side chain, but also
affects the overall backbone conformation of the mutant peptide
with a backbone RMSDE3.1 Å (Fig. S17c). This potentially disrupts
the speciﬁc “cation-π”, as well as the hydrogen bond interactions
between the K4 and F2757.28. As a result, M6 occupies the crucial
pocket on the ECS (Fig. S17d), forcing an unfavorable anchoring of
the mutant peptide, driven by the non-speciﬁc K185-F3 “cation-π”
interaction (Fig. 5b). This explains the known inactivity of
YSFkPMPLaR toward C5aR [78].
3.11. Comparison of the “site2” on C5aR with CXCR4
The interaction of SDF-1 with CXCR4 is also believed to involve
a similar two site binding interaction [7], as hypothesized for C5a
and C5aR [24]. Thus, the peptide agonist bound “site2” on C5aR
was compared against the cyclic peptide antagonist bound “site2”
on CXCR4. As illustrated in Fig. 4b, the peptide agonist bound C5aR
displays an extended and open active “site2” on ECS, similar to the
“site2” observed in CXCR4, but in sharp contrast with the “site2”,
previously hypothesized for C5aR [24]. As evidenced in Table 1,
total 23 residues (6 N-terminus, 8 ECL2, 5 ECL3 and 4 TM7
residues) contribute toward the “site2” on C5aR that present a
solvent accessible surface area (SASA) of 899 Å2 to the linear
peptide agonist, roughly comparable to the SASA of the “site2”
bound to the cyclic peptide CVX15 on CXCR4 (20 residues,
SASAE606 Å2). The ECLs and N-terminus residues are the
Fig. 4. The peptide agonist bound meta-active state of C5aR. (a) The meta-active conformer of C5aR in complex with the peptide agonist illustrated in ribbon diagram.
(b) C5aR surface rendered in ionizability mode highlights the YSFKPMPLaR (a¼D-Ala) agonist (green) at the “site2”. The crucial pocket on the ECS occupied by the K4 of the
agonist is also highlighted.
Fig. 5. (a) Speciﬁc interactions driving the selective binding of the YSFKPMPLaR agonist (green) at the “site2” of C5aR. (b) Nonspeciﬁc intermolecular interactions displayed
by the mutant peptide (cyan) at the “site2” of C5aR. Interacting residues of C5aR (gray) are respectively shown in sticks, highlighting the cation–π (solid red) and salt bridge/
hydrogen bond (dotted black) interactions. Snapshots of the respective binding pockets are also illustrated in Fig. S17.
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major contributors toward the “site2” on C5aR that includes only
4 residues from the extracellular stems of TM7, whereas the “site2”
on CXCR4 has signiﬁcant contribution from the extracellular part
of the helices 3, 4, 5 and 7. In fact 14 out of the 20 residues in
“site2” on CXCR4 are from the transmembrane helices. This is not
surprising, as the ICL3 engineered antagonist bound inactive
CXCR4 has a more open topology than the peptide agonist bound
C5aR. As evidenced from the SASA calculation (Table 1) the
inactive C5aR has a relatively closed topology, similar to the
inactive CXCR1. Thus, it is not surprising that agonist binding at
the “site2” on meta-active conformer of C5aR involves more
number of residues from the N-terminus and loops than from
the extracellular parts of the transmembrane helices. Indeed,
literature evidences that mutation of many residues [25,45–
47,80] (T29, D191, P270, S272, F275, N279, F182 and P184)
identiﬁed on “site2” of C5aR (Table 1) affect C5aR signaling. In
addition, the residues that are sequentially close to “site2” but
appear apparently farther from the “site2” [28,80] (D27, L277, and
D282) in our model are also known to affect the C5aR signaling in
response to C5a. It is quite possible that such residues may be
structurally important to C5aR or other sections of C5a might be
engaging these residues for tighter binding and signaling of C5aR.
This further conﬁrms the exceptional quality of the meta-active
conformer of the C5aR.
3.12. Rationalizing the YSFKPMPLaR agonist binding to C5aR in light
of C5a
It is important to note that a full agonist like C5a can potentially
access the “site1” and “site2”, whereas the linear peptide agonist
can only access the “site2” on C5aR (Figs. 4b and 5a). Thus, unlike
the mutant peptide [78] (Fig. 5b, Table S10), mutation of K68 to
E68/M68 in C5a does not induce complete inactivity [33], rather
decreases the ED50 value, respectively by 2.5 and 6.8 fold toward
C5aR. Similarly, the des-R74-C5a with intact stereochemistry at
K68 displays relatively weak binding and signaling [33,34,48]
compared to C5a (Table S11), which abrogates completely by
further mutation of K68/E68 [33], suggesting the functional
importance of K68 over R74 in C5a for C5aR signaling. Further,
the loss of signaling (100 fold) in D191G-C5aR [25] in response
to W5Cha (Me-F-K-P-dCha-Cha-dR; dR¼D-Arg), clearly justiﬁes
the role of D191 in C5aR for anchoring the agonist by involving the
dR6 on W5Cha. In agreement, the R10 on YSFKPMPLaR agonist
also demonstrates interaction with D191 (Fig. 5a) in our studies,
which could also be the case for R74 on C5a. This brings back the
attention to D282 of C5aR, previously suggested to interact with
R74 of C5a or other related peptides [28,31]. However, a closer
analysis of the binding and signaling data of D282 mutants
suggests an alternative mechanism. As evidenced, both wild type
and D282A-C5aR bind to C5a with identical afﬁnity (IC5014 nM),
which clearly indicates the negligible role of D282 in anchoring
R74 of C5a to C5aR. Moreover, compared to wild type C5aR
(EC505.82 nM), the D282A-C5aR demonstrates3 fold weaker
signaling (IC5014.6 nM) in response to C5a. But, surprisingly
D282A-C5aR demonstrates better signaling (91% degranulation)
than the wild type C5aR (79% degranulation) in response to des-
R74-C5a. Further, R74D-C5a does not bind to D282R-C5aR, but
demonstrates weaker binding to wild type C5aR (IC503790 nM).
It is noteworthy that both C5a (EC50325 nm, IC5057 nm) and
R74D-C5a (EC50365 nM, IC50not known) trigger comparable
signaling activity in D282R-C5aR. In summary, the reported func-
tional data on D282 mutants does not favorably support or
establish a direct interaction between D282 of C5aR with R74 of
C5a. This is further in support of the C5aR–peptide agonist
complex (Fig. 5a), where it is demonstrated that the R10 of the
YSFKPMPLaR agonist interacts with the D191 at the “site2” of
C5aR, instead of the D282, which is positioned little deeper into
the transmembrane region in the model. GPCRs are conforma-
tionally dynamic and are known to demonstrate allosterism [81].
Thus, it is quite possible that mutations of structurally important
residues such as D282 in C5aR can induce allosterism, which can
modulate the overall pharmacology of C5aR in response to C5a.
Though 3D models provide important insights, only future struc-
tural studies can unequivocally establish the functional impor-
tance of many such residues and their contribution toward ligand
binding and allosterism in C5aR.
Nevertheless, the speciﬁcity of the intermolecular interactions
illustrated for the C5aR–peptide complex (Fig. 5a) was maintained
over 250 ns in POPC bilayer (Figs. 6, 7, S18, S19 and S20). Besides
the general hydrophobic and hydrogen bonding interactions, the
moderate “cation-π” interaction evolved between the Y1-R34 side
chains (Figs. 7a and 7b) by the disappearance of the weak
hydrogen bonding between the side chain of Y1 and backbone
carbonyl of R34 (Fig. 7c) during the MD simulation also contribute
toward the overall stability of the complex. Moreover, the strong
K4-F2757.28 “cation-π” (dr6 Å; Θo901) and hydrogen bonding
interactions between the side chain of K4 and backbone carbonyl
of F2757.28 (Fig. 6), including the transient R10-D191 salt bridge
interaction (Fig. 7g), immensely strengthen the speciﬁc binding
mode demonstrated by the peptide agonist in C5aR complex
(Figs. 4 and 5a).
Moreover, previous studies have also shown that K4/E4 muta-
tion in the peptide agonist dampens the C5aR signaling, which is
further rescued to a great extent by R4 with a cationic side chain
[78]. In addition, F275A mutation has also been suggested to have
a deleterious effect on C5aR function [46]. It is worth mentioning
that similar to the des-R74-C5a, the removal of R10 from the
peptide agonist reduces the estimated afﬁnity by30 fold toward
Table 1
Solvent accessible surface area (SASA)a of the ECS in C5aR, respectively compared with the CXCR1 and CXCR4. The SASA of the “site2” in C5aR is also compared with the
“site2” observed in CXCR4.
GPCRs (PDB) SASA (Å2) Active site residues
ECS (No. of residues) Site2 (No. of residues)
CXCR1 (2LNL) 2286 (67)
CXCR4 (3OE0); Bound to cyclic
peptide antagonist CVX15
3238 (60) 606 (20) [H1133.29, Y1163.32, T1173.33, D1714.60, D187, R188, F189, Y190, P191, D193, V1965.35,
F1995.38, Q2005.39, D2626.58, L2666.62, E2777.28, H2817.32, I2847.35, S2857.36, E2887.39]
C5aR (Inactive) 2739 (70)
C5aR (Meta-active); Bound to
linear peptide agonist
2660 (70) 899 (23) [T29, S30, N31, T32, R34, V35, Y174, R175, F182, P184, K185, V186, V190, D191,
L268, E269, P270, S271, S272, F2757.28, L2767.29, L2787.31, N2797.32]
a¼SASA calculations are done using the default van der Waals radii with Ala–X–Ala template as reference in Naccess; TM residues shown in bold are numbered following
Ballesteros–Weinstein system.
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the meta-active conformer of C5aR (data not shown). Thus, it
is implied that while R10/R74 helps in docking the agonist, the
K4/K68 plays an important role in triggering the binding and
signaling at the “site2” involving F2757.28 in C5aR. Moreover,
comparison of the bound peptide agonist with the unbound C-
terminus of C5a [27] (Fig. S21) reveals an incredible similarity
between the side chain conformations of R10/R74, K4/K68, S2/S66
and M6/M70 residues. Indeed, the speciﬁcity of the binding
demonstrated by the peptide agonist at the “site2” of C5aR is also
reﬂected by the native C-terminus peptide (NISHKDMQLGR) of C5a
(data not shown).
3.13. Activation mechanism in C5aR compared to other GPCRs
Random saturation mutagenesis studies on the ECL2 of C5aR
have suggested that the ECL2 works as a gatekeeper and signiﬁ-
cant movement in ECL2 is associated with auto-activation of C5aR
[25]. In addition, single or double mutation in TM3 has also been
shown to auto-activate C5aR [42,82]. As noted in Fig. 8a, with a
backbone RMSD of 2.54 Å, the transition from the inactive to
meta-active conformer in C5aR not only displays the movement of
the ECL2, but also displays signiﬁcant movements in N-terminus
and other ECLs. Interestingly, a backbone RMSD of E1.3–2.6 Å,
coupled with signiﬁcant movements of helices and loops, is also
noted across the known inactive and agonist bound meta-active
conformers of GPCRs (Fig. 8b). The conformational dynamics in
POPC bilayer provided both the inactive and the meta-active
conformer of the C5aR, with no direct inﬂuence from the peptide
agonist. Thus, we hypothesize that perhaps agonist binding in
C5aR follows a conformational selection approach than an induced
ﬁt approach [44]. This appears plausible as many GPCRs in native
and non-native tissues display some amount of basal activity,
which further enhances in response to the ligand or to an
activating point mutation [83]. However, whether ligand binding
in GPCR is universally conformational selection based is a matter
of challenging structural studies of active GPCRs, both in ligand
free and in bound states.
Analysis of the change in interhelical angles (ΔΘ¼Θinactive
ΘActive) of known GPCR pairs, summarized in Table S12 indicate that
inactive-to-meta-active transition involves the movement of almost all
the helices across the GPCR pairs, including the model C5aRs.
However, the highest number of signiﬁcant movements (ΔΘZ741)
are noted for the helix6 in opsin [6], helix1, helix6 in β2AR [5,10],
helix7 in A2A [9,11], and helix5 in M2R [15,19], compared to TM3, and
TMs 5–7 in C5aR. In agreement with the popular activation mechan-
ism [84], the helix3–helix6 pair displays signiﬁcantly higher magni-
tude of change in ΔΘ (ΔΘE7.91 for rhodopsin, 8.51 for A2A and
9.41 for β2AR). However, it is noted that the ΔΘ related to helix3–
helix6 pair is not consistently highest across the GPCR pairs. Surpris-
ingly, only M2R (ΔΘE-22.21) display the highest magnitude of change
Fig. 6. The stability of the speciﬁc intermolecular interactions monitored between the K4 of the YSFKPMPLaR agonist with the F2757.28 of C5aR, over 250 ns of MD at 300 K in
POPC bilayer. The distance (a) and the interaction angle (b) monitored between the K4 head group and aromatic ring of F2757.28 indicates a strong K4-F2757.28 “cation–π”
interaction. (c) The strong hydrogen bond interaction between the K4 head group and the backbone carbonyl of F2757.28. (d) The distance between the heavy atoms
participating in the hydrogen bonding.
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for helix3–helix6 pair, whereas the highest is noted for the helix5–
helix6 in opsin (ΔΘE13.51), helix6–helix7 in β2AR (ΔΘEþ17.21),
and helix6–helix7 pair (ΔΘEþ16.71) in A2A. Interestingly, the TM3–
TM6 pair displays the highest magnitude of change (ΔΘEþ11.11) in
C5aR, which does not feature the “ionic lock” mostly attributed
for the activation of the above mentioned receptors. This analysis
suggests, perhaps there is no uniform mechanism that operates across
the GPCRs and also highlights the complexity involved
in GPCR activation. Thus, it can be implied that the nature and
the type of the agonist play an important role in regulating
the population of GPCR microstates, which in turn chooses an
activation mechanism [85] suitable for the tissues expressing
the GPCRs.
4. Conclusions
Highly reﬁned model structures of C5aR are reported for the
ﬁrst time in excellent correlation with experiments, both in
inactive state and in complex with a stereochemically engineered
linear YSFKPMPLaR agonist [26], carved out of the C-terminus of
C5a [27]. The meta-active conformer of C5aR with an atomistic
resolution of “site2” on ECS provides important structural insights
not appreciated before for understanding the selectivity of agonist
binding and signaling. The conformational transition from inactive
to meta-active state in C5aR, which facilitates the agonist binding
and activation not only involves the movements of TM3–TM6
(ΔΘEþ11.11) but also involves the movement of N-terminus,
Fig. 7. The other intermolecular interactions monitored between the YSFKPMPLaR agonist and the C5aR, over 250 ns of MD at 300 K in POPC bilayer. NH3þ and CO2
respectively represent the N and C-terminus of the peptide agonist. Y1, S2, and R10, respectively represent the interacting residues on the peptide. T32, R34, K185, D191, and
E269, respectively represent the interacting residues on the C5aR. Demonstration of the distance (a) and angle (b) of the moderate “cation–π” interaction observed between
the Y1-R34 side chains, by depletion of the weak hydrogen bonding (c) between the Y1 (HH)-R34 (CO). (d) The strong hydrogen bonding demonstrated between the back
bone NH of S2 and the side chain of E269. (e) The strong hydrogen bonding between the side chains of S2 and T32 is maintained modestly over the 50% of the time. (f) The
presence of hydrogen bond between the N-terminus and the side chain of E269 implicates the existence of a strong salt bridge interaction between NH3þ-E269. (g) The
transient nature of hydrogen bonding between the side chain of the R10 and D191 suggest the presence of a salt bridge interaction between R10-D191. (h) The strong
hydrogen bond interaction between the C-terminus of the peptide agonist and the side chain of K185 is modestly maintained over 20% of the time.
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ECL2 and other ECLs. The study highlights F2757.28 and D191 as
major residues on C5aR for anchoring the K4 and R10 of the
peptide agonist and also suggests a similar binding mechanism
between C5a and C5aR.
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Fig. 8. Illustration of the conformational changes (movements in TMs, N-terminus and ECLs) highlighting the backbone RMSDs involved in transition of inactive to agonist
bound meta-active conformer in C5aR in light of other GPCRs. (a) the meta-active (raspberry, ECL2 in red) and inactive (slate, ECL2 in cyan) conformers of the model C5aRs,
and (b) the meta-active (3DQB, deep salmon) and inactive (1F88, wheat) conformers of rhodopsin (top left), the meta-active (3P0G, light blue) and inactive (2RH1, lime
green) conformers of β2 AR (top right), the meta-active (4MQS, salmon) and inactive (3UON, cyan) conformers of M2R (bottom right), the meta-active (3QAK, yellow orange)
and inactive (3REY, violet) conformers of A2A (bottom left).
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